Charles River Laboratories stock (US1591881009): Q1 earnings beat with updated FY guidance

Charles River Laboratories reported Q1 2026 revenue of $995.8 million, beating estimates by 1.9%, and EPS of $2.06, topping consensus. Shares traded flat post-results amid updated full-year outlook.

Charles River Laboratories released its Q1 2026 earnings on May 7, 2026, posting revenue of $995.8 million, up 1.2% year-over-year and above the consensus estimate of $977.4 million, according to MarketBeat as of May 2026. Earnings per share came in at $2.06, surpassing expectations of $1.96 by $0.10. The company also updated its FY 2026 guidance to EPS of $10.80-$11.30 and revenue of $3.8-$3.9 billion. The stock remained flat at $158.00 immediately following the results, as noted in StockStory as of May 2026.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Charles River Laboratories International, Inc.
• Sector/industry: Healthcare / Life sciences services
• Headquarters/country: United States
• Core markets: North America, Europe
• Key revenue drivers: Research models, safety assessment, discovery services
• Home exchange/listing venue: NYSE (CRL)
• Trading currency: USD

Charles River Laboratories: core business model

Charles River Laboratories provides essential products and services that speed up research and drug development for pharmaceutical and biotechnology firms. Founded in 1947 and named after a Massachusetts river, the company offers research models, discovery and safety assessment services, and manufacturing support, according to StockStory research report as of May 2026. These services support non-clinical stages of drug development, helping clients bring therapies to market faster. With a market capitalization of $7.80 billion as of the latest data, it plays a key role in the life sciences ecosystem.

The business spans three main segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. RMS supplies purpose-bred laboratory animals and related services, while DSA focuses on preclinical testing. This integrated model allows Charles River Laboratories to serve over 80% of the top 20 pharma companies by revenue, providing stability through long-term contracts.

Main revenue and product drivers for Charles River Laboratories

Revenue is primarily driven by DSA services, which accounted for the bulk of Q4 CY2025 sales at around $994.2 million total, flat year-over-year but beating estimates, per StockStory as of May 2026. Organic revenue dipped 2.6% in that period, reflecting cautious client spending in biotech. Key drivers include demand for safety assessment amid rising drug pipelines and cell/gene therapy testing. Q1 2026 revenue growth of 1.2% signals stabilization.

Research models remain a steady contributor, benefiting from the company's leadership in genetically modified models for oncology and neurology research. Non-GAAP EPS of $2.39 in Q4 CY2025 exceeded estimates by 1.9%, highlighting operational efficiency despite flat sales.

Industry trends and competitive position

The preclinical services market is growing due to increased R&D in biologics and advanced therapies, with Charles River Laboratories holding a strong position as one of the largest contract research organizations (CROs). Its scale enables investment in automation and digital tools, improving throughput for US-based pharma clients reliant on efficient outsourcing.

Why Charles River Laboratories matters for US investors

Listed on NYSE, Charles River Laboratories offers US investors exposure to the booming life sciences sector, which supports the domestic biotech industry. With heavy revenue from North American clients and headquarters in Wilmington, Massachusetts, it benefits from US FDA approvals and NIH funding trends.

Conclusion

Charles River Laboratories delivered a Q1 earnings beat with revenue and EPS above consensus, alongside FY 2026 guidance that brackets analyst expectations. While recent quarters show modest growth amid biotech funding caution, the company's entrenched role in preclinical services positions it for recovery in drug development pipelines. Investors track upcoming catalysts like client NCE starts and segment performance.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.